40 articles, transcripts, and reports
Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB)…
Biogen, Inc. (NASDAQ: BIIB) Q3 2021 earnings call dated Oct. 20, 2021 Corporate Participants: Michael Hencke — Investor Relations Michel Vounatsos — Chief Executive Officer Alfred Sandrock — Head of Research…
Biogen Inc. (NASDAQ: BIIB) Q2 2021 earnings call dated Jul. 22, 2021 Corporate Participants: Mike Hencke — Director of Investor Relations Michel Vounatsos — Chief Executive Officer Alfred Sandrock — Head…
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Thursday said its second-quarter earnings and revenues decreased from last year. The results, however, came in above analysts’ forecast.…
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in…
Biogen Inc. (NASDAQ: BIIB) Q1 2021 earnings call dated Apr. 22, 2021 Corporate Participants: Mike Hencke — Director of Investor Relations Michel Vounatsos — Chief Executive Officer Alfred W.…
Biogen Inc. (NASDAQ: BIIB) reported first quarter 2021 earnings results today. Total revenues decreased 24% year-over-year to $2.6 billion. On a constant currency basis, revenues…
Biogen, Inc. (NASDAQ: BIIB) Q4 2020 earnings call dated Feb. 03, 2021 Corporate Participants: Mike Hencke — Director, Investor Relations Michel Vounatsos — Chief Executive Officer Alfred W. Sandrock — Executive Vice…
Biogen, Inc. (NASDAQ: BIIB) Q4 2020 earnings call dated Feb. 03, 2021 Corporate Participants: Mike Hencke — Director, Investor Relations Michel Vounatsos — Chief Executive Officer Alfred W. Sandrock — Executive…
Biogen (NASDAQ: BIIB) reported fourth-quarter 2020 financial results before the opening bell on Wednesday. The biotechnology giant reported a 22% decline in Q4 revenues to…
